Steven Woloshin, MD, MS, a professor of medicine and community and family medicine, and co-director of the Master of Health Care Delivery Science program at The Dartmouth Institute for Health Policy and Clinical Practice, discusses the controversy surrounding the FDA’s approval of Aducanumab—a new drug to treat mild Alzheimer disease.
A team of researchers at Dartmouth’s Geisel School of Medicine and New York University (NYU) Grossman School of Medicine has received a $4 million grant from the National Institute on Aging to improve “triadic” interactions between patients living with dementia, their care partners, and their clinicians.
Upcoming EventsThis page may link to PDF files. Use this link to download Adobe Reader if needed.